Equillium to Present at the SVB Securities Annual Global Healthcare Conference
February 07 2023 - 8:00AM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders with high unmet medical need,
today announced that it will present at the SVB Securities Annual
Global Biopharma Conference.
Management will provide a recap of the recent partnership
agreement with Ono Pharmaceuticals, and an overview of the
multi-cytokine inhibitor platform focused on EQ101 for the
treatment of alopecia areata and EQ102 for the treatment of celiac
disease, as well as upcoming catalysts and milestones. Management
will also be available for one-on-one meetings during the
conference.
Conference:
SVB Securities Global Biopharma
Conference
Location:
Virtual
Date:
Tuesday, February 14
Time:
10:00 am Pacific Time | 1:00 pm Eastern
Time
Webcast access will be available on the “Events &
Presentations” page under the Investor Relations tab on the
Company’s website at
https://www.equilliumbio.com/investors/events-and-presentations/default.aspx.
An archived replay of both conferences will be available for 90
days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel first-in-class immunomodulatory assets targeting
immuno-inflammatory pathways. EQ101: a tri-specific cytokine
inhibitor that selectively targets IL-2, IL-9, and IL-15; currently
under evaluation in a Phase 2 proof-of-concept study of patients
with alopecia areata. EQ102: a bi-specific cytokine inhibitor that
selectively targets IL-15 and IL-21; currently under evaluation in
a Phase 1 study to include healthy volunteers and celiac disease
patients. Itolizumab: a monoclonal antibody that targets the
CD6-ALCAM signaling pathway which plays a central role in the
modulation of effector T cells; currently under evaluation in a
Phase 3 study for patients with acute graft-versus-host disease
(aGVHD) and a Phase 1b study for patients with lupus/lupus
nephritis. Equillium acquired rights to itolizumab through an
exclusive partnership with Biocon Limited and has entered a
strategic partnership with Ono Pharmaceutical Co., Ltd. for the
development and commercialization of itolizumab under an exclusive
asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of Equillium’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include:
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; and whether the results
from clinical studies will validate and support the safety and
efficacy of Equillium’s product candidates. These and other risks
and uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in Equillium's filings and reports, which
may be accessed for free by visiting the Securities and Exchange
Commission’s website at www.sec.gov and on Equillium’s website
under the heading “Investors.” Investors should take such risks
into account and should not rely on forward-looking statements when
making investment decisions. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Equillium undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230207005451/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2023 to Apr 2024